Cancer Immunotherapy

Erscheinungsjahr 2019
ISBN: 978-0-12-816575-1
Verlag: ACADEMIC PR INC

Buch, Englisch, Band 164, 354 Seiten, Format (B × H): 152 mm x 229 mm, Gewicht: 700 g

Reihe: Progress in Molecular Biology

Cancer Immunotherapy, Volume 165 in the Progress in Molecular Biology and Translational Science series, provides informative monographs on a variety of research topics related to different approaches to cancer immunotherapy, with this release focusing on TNFR2 in cancer immunology and immunotherapy, From the Hellstrom paradox towards cancer cure, CAR T-cell treatment of T-cell malignancy, Immunotherapy of pancreatic cancer, Cancer stem cell immunology/immunotherapy,

Cytokine release syndrome, Tumor cell-based mechanisms of resistance to immune attack, and Mushroom compounds in cancer immunotherapy.

Zielgruppe

<p>Each volume of Progress in Molecular Biology and Translational Science will be useful for scientists working actively in a field, including those at levels ranging from graduate student to senior investigator. Volumes also are appropriate for new investigators to a field who wish to familiarize themselves with the latest work.</p>

Autoren/Hrsg.

Teplow, David B.

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Immunologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung

Inhaltsverzeichnis

1. TNFR2 in cancer immunology and immunotherapy Xin Chen 2. From the Hellstrom paradox towards cancer cure Ingegerd Hellstrom and Karl Erik Hellstrom 3. CAR T-cell treatment of T-cell malignancy Martin Pule 4. Immunotherapy of pancreatic cancer Jorg Kleeff 5. Cancer stem cell immunology/immunotherapy Federica Cavallo 6. Cytokine release syndrome Alexander Shimabukuro-Vornhagen 7. Tumor Cell-Based Mechanisms of Resistance to Immune Attack Louis M. Weiner 8. Mushroom compounds in cancer immunotherapy Peter Amwoga Ayeka

Über Autor(innen)

Teplow, David B.
David B. Teplow, Ph.D., is a Professor of Neurology, Emeritus, at UCLA and an internationally recognized leader in efforts to understand and treat Alzheimer's disease. Dr. Teplow's group has used a multi-disciplinary approach to determine how neurotoxic peptides, such as the amyloid ?-protein (Alzheimer's disease) and ?-synuclein (Parkinson's disease), form neurotoxic structures that kill neurons and to develop the means to block these processes. Dr. Teplow received undergraduate training at UC Berkeley; a Ph.D. from the University of Washington; and was a postdoctoral scholar at Caltech. Before coming to UCLA, Dr. Teplow was a faculty member in the Department of Neurology, Harvard Medical School. Dr. Teplow has published >250 peer-reviewed articles, books and book chapters, and commentaries, in addition to serving on numerous national and international scientific advisory boards. Dr. Teplow was a founding editor of the Journal of Molecular Neuroscience and Current Chemical Biology, He is Co-Editor-in-Chief of the Elsevier serial Progress in Molecular Biology and Translational Science and is Associate Editor-in-Chief of the American Journal of Neurodegenerative Disease.